Burning Rock Biotech Limited American Depositary Shares (BNR)
FairStock Score: 49/100 — MIXED
Key Financials
| Current Price | $11.82 |
| Market Cap | $222M |
| P/E Ratio | -14.07 |
| ROE | -12.82% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I start with the business and the numbers. Burning Rock sells NGS-based cancer therapy selection tests, but the financials show a firm under stress. In the latest reported quarter, 2026-Q1, revenue was $107.9 million and net income was -$17.5 million, a -16.19% net margin. The provided growth figures for the latest available period show revenue growth of -18.89% and profit growth of -29.42%, so the trajectory is shrinking, not compounding. At the 2026-10-13 close of $15.00, market cap is $222 million; the FairStock-calculated P/E is -17.86 and P/B is 2.20. Those are not the numbers of a cash-generating bargain. FairStock-calculated ROE is -12.82% and ROCE is -5.16%, meaning the business is not earning a return on capital. Free cash flow is -$39.5 million trailing twelve months, a FairStock-calculated FCF yield of -17.8%; that burns equity. The balance sheet is the one comfort: debt/equity is only 0.09. But Piotroski 1/9 and Altman -6.33 point to weak fundamentals and financial distress risk. Growth is not just slow; it is negative. There is no long filed record for a Lynch category; only zero years of filed results are available. The 52-week range of $6.79-$41.72 and beta of 1.39 show Mr. Market has been volatile. Without positive owner earnings or a durable record, I see no margin of safety at 2.20 times book. Low debt gives time, but time without improving cash flow is not an asset.
In plain English: Burning Rock Biotech develops and sells cancer tests in China and the United States. The business looks weak right now: it is losing money, sales are falling, and it burns cash. At $15 a share, the price does not look clearly cheap compared with those weak numbers.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer